Stock analysts at Maxim Group decreased their target price on shares of ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC) from $12.00 to $4.00 in a report issued on Monday. The firm currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 238.98% from the stock’s previous close. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) weekly performance is -10.45%. On last trading day company shares ended up $1.20. Analysts mean target price for the company is $5.69. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) distance from 50-day simple moving average (SMA50) is -1.53%.
Shares of the DNA vaccine maker Inovio Pharmaceuticals Inc. (NYSEMKT:INO) have reportedly completed their 1 for 4 reverse split and are set to start trading at a higher price this morning. What’s key to understand is that stocks tend to be highly volatile following reverse splits and today’s action in Inovio probably won’t stray from this trend. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares advanced 326.41% in last trading session and ended the day on $9.85. INO return on assets is -71.90%.Inovio Pharmaceuticals Inc. (NYSEMKT:INO) quarterly performance is -27.57%.
On May 22, 2014, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) or the Company, announced the presentation of results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares moved up 7.77% in last trading session and was closed at $4.02, while trading in range of $3.58 – $4.10. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) year to date (YTD) performance is -7.37%.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, on 8 may updated its drug development progress and reported financial results for the three months ended March 31, 2014. Net loss for the three months ended March 31, 2014 was $30.8 million, or $0.06 per share, compared to a net loss of $26.0 million, or $0.05 per share, in the corresponding period in 2013. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended the last trading day at $1.46. Company weekly volatility is calculated as 6.18% and price to cash ratio as 5.84.Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) showed a positive weekly performance of 10.61%.
Omeros Corporation (NASDAQ:OMER) Director Thomas J. Cable unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.80, for a total transaction of $59,000.00. Following the completion of the sale, the director now directly owns 62,067 shares in the company, valued at approximately $732,391. Omeros Corporation (NASDAQ:OMER) weekly performance is 14.03%. On last trading day company shares ended up $13.33. Analysts mean target price for the company is $25.40. Omeros Corporation (NASDAQ:OMER) distance from 50-day simple moving average (SMA50) is 14.62%.